InnoCare Pharma Limited (9969.HK)

HKD 6.1

(0.16%)

EBITDA Summary of InnoCare Pharma Limited

InnoCare Pharma Limited's latest annual EBITDA in 2023 was -516.55 Million CNY , up 38.59% from previous year.
InnoCare Pharma Limited's latest quarterly EBITDA in 2024 Q1 was -147.36 Million CNY , down -24.67% from previous quarter.
InnoCare Pharma Limited reported an annual EBITDA of -808.27 Million CNY in 2022, down -10100.27% from previous year.
InnoCare Pharma Limited reported an annual EBITDA of 16.23 Million CNY in 2021, up 101.82% from previous year.
InnoCare Pharma Limited reported a quarterly EBITDA of -133.18 Million CNY for 2024 Q2, up 20.62% from previous quarter.
InnoCare Pharma Limited reported a quarterly EBITDA of N/A for 2023 FY, up 38.59% from previous quarter.

Annual EBITDA Chart of InnoCare Pharma Limited (2023 - 2017)

Historical Annual EBITDA of InnoCare Pharma Limited (2023 - 2017)

Year	EBITDA	EBITDA Growth
2023	-516.55 Million CNY	38.59%
2022	-808.27 Million CNY	-10100.27%
2021	16.23 Million CNY	101.82%
2020	-453.43 Million CNY	78.85%
2019	-2.14 Billion CNY	-290.89%
2018	-547.18 Million CNY	-63.05%
2017	-335.61 Million CNY	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-147.36 Million CNY	-24.67%
2024 Q2	-133.18 Million CNY	20.62%
2023 FY	- CNY	38.59%
2023 Q4	-118.2 Million CNY	-88.2%
2023 Q3	-62.8 Million CNY	85.04%
2023 Q1	2.59 Million CNY	100.69%
2023 Q2	-419.71 Million CNY	-16301.77%
2022 Q4	-373.51 Million CNY	-500.93%
2022 Q3	-62.15 Million CNY	63.36%
2022 Q2	-169.62 Million CNY	-16.74%
2022 Q1	-145.29 Million CNY	44.12%
2022 FY	- CNY	-10100.27%
2021 Q1	-135.82 Million CNY	0.21%
2021 Q3	360.65 Million CNY	365.53%
2021 Q4	-259.99 Million CNY	-172.09%
2021 Q2	-135.82 Million CNY	0.0%
2021 FY	- CNY	101.82%
2020 FY	- CNY	78.85%
2020 Q1	-142.34 Million CNY	90.48%
2020 Q3	-136.11 Million CNY	4.38%
2020 Q2	-142.34 Million CNY	0.0%
2020 Q4	-136.11 Million CNY	0.0%
2019 Q3	-324.2 Million CNY	-487.93%
2019 Q2	-55.14 Million CNY	0.0%
2019 Q1	-55.14 Million CNY	39.38%
2019 FY	- CNY	-290.89%
2019 Q4	-1.49 Billion CNY	-361.11%
2018 Q3	-46.97 Million CNY	-37.76%
2018 Q4	-90.96 Million CNY	-93.65%
2018 Q1	-34.09 Million CNY	0.0%
2018 Q2	-34.09 Million CNY	0.0%
2018 FY	- CNY	-63.05%
2017 FY	- CNY	0.0%

Peer EBITDA Comparison of InnoCare Pharma Limited

Name	EBITDA	EBITDA Difference
Uni-Bio Science Group Limited	91.23 Million HKD	666.186%
CK Life Sciences Int'l., (Holdings) Inc.	486.79 Million HKD	206.113%